Trial Profile
Combination Antibody Therapy With Apolizumab (1D10) And Rituximab (CD20) In Relapsed Lymphoma And CLL
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Apolizumab (Primary) ; Rituximab (Primary) ; Dexamethasone; Diphenhydramine; Paracetamol
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 18 Mar 2017 Status changed from completed to discontinued.
- 18 Mar 2017 Status changed from completed to discontinued.
- 29 Sep 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.